Hygon Mutavhatsindi1,2*
Muki Shey2,3,4- 1Biomedical Research and Innovation Platform (BRIP), South African Medical Research Council, Tygerberg, South Africa
- 2Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- 3Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- 4Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Introduction
The co-epidemic of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) remains one of the major barriers to global TB eradication. T2DM triples the risk of developing active TB (1), complicates treatment, and is associated with delayed cure and increased mortality (2, 3). While epidemiological studies have long defined the clinical scope of this syndemic, the precise immunological mechanisms remain unclear. A recent pilot study by Ogongo and colleagues (4) provides compelling cellular-level insight into this issue, reporting increased frequencies of circulating Th17 cells and altered total CD4 T cell maturation and differentiation in active TB patients with T2DM. Their findings call for a shift in perspective, recognizing T2DM not merely as a metabolic comorbidity but as an active immunomodulatory condition with major implications for TB pathogenesis, diagnosis, and host-directed therapy (HDT).
The compromised gatekeeper: T-cell dysfunction and LTBI progression
Protective immunity against Mycobacterium tuberculosis (M. tuberculosis) is essential and relies on a successful, sustained T helper 1 (Th1) response. The Th1 axis, driven by Interferon-γ (IFN-γ), is essential for macrophage activation and the formation of the granuloma, the structure responsible for containing latent infection.
The observation that T2DM leads to altered CD4 T cell maturation and differentiation is arguably the most impactful finding from a public health perspective, as it offers a molecular mechanism for the increased risk of latent TB infection (LTBI) progression to active TB. Sustained latency relies on a population of durable, highly functional Th1 memory T cells (5, 6). The diabetic microenvironment, characterized by chronic hyperglycaemia and systemic inflammation, fundamentally disrupts T-cell immunometabolism (7). T cells exposed to chronic hyperglycaemia become increasingly glycolysis-dependent, a metabolic state that favours dysfunctional differentiation trajectories and can promote exhaustion phenotypes (8). Studies have shown that antigen-specific T-cell responses are diminished in latent TB co-infected with T2DM (8–10).
If T2DM compromises the terminal differentiation and survival of these protective Th1 memory cells, the immune surveillance required to contain dormant bacilli within the granuloma is critically impaired. The failure to maintain a high-quality, long-lived Th1 population suggests a permissive immunological environment that facilitates M. tuberculosis reactivation, directly connecting the metabolic status of the host to the failure of adaptive immunity to maintain latency. It is important to note that the immunological profiles characterized in the pilot study by Ogongo and colleagues represent total circulating CD4+ T-cell phenotypes rather than M. tuberculosis-specific or lung-resident populations. While these peripheral markers provide valuable insights into systemic immune dysregulation in T2DM, they may not fully reflect the antigen-specific responses or the localized inflammatory landscape within the lung parenchyma.
Immune deviation: Th17 and the failure to cure
In active TB, the prognosis in T2DM patients is consistently worse, characterized by delayed sputum conversion, higher rates of treatment failure, and increased tissue damage (2, 3). The observed pathological shift toward increased frequencies of circulating Th17 cells provides a systemic biological correlate for these adverse clinical outcomes (2, 3).
However, the role of Th17 cells in TB is complex and context-dependent. While early Th17-mediated responses are essential for mucosal immunity and the initial recruitment of protective neutrophils to the site of infection, the efficacy of this axis follows a “Goldilocks” principle where both deficiency and excess of IL-17 can lead to clinical detriment (11). In the context of active tuberculosis-diabetes mellitus (TB-DM), the observed Th17 expansion appears to be a detrimental immune deviation rather than an effective protective response.
Chronic, misdirected inflammation driven by IL-17 is strongly associated with the matrix metalloproteinase (MMP) cascade, including heightened MMP-9 and MMP-1 activity often observed in T2DM, which is the central driver of cavitary, destructive lung disease. We posit that the chronic metabolic inflammation inherent to T2DM serves as a pathological driver that shifts the Th17 response away from its protective homeostatic baseline toward the hyper-inflammatory, maladaptive phenotype reported by Ogongo and colleagues. The excessive tissue pathology seen in TB-DM co-infection, often leading to permanent lung damage and functional decline is thus explained not by a lack of inflammation, but by an inappropriate type of inflammation.
Furthermore, this deviation skews the T-cell differentiation landscape toward the Th17 lineage, often at the expense of the protective Th1 lineage. These findings suggest that T2DM may exert a dual detrimental effect, potentially attenuating the Th1-mediated protective response while amplifying Th17-driven inflammatory pathology. This overall imbalance between impaired Th1 immunity and exaggerated Th17 inflammation in TB-DM is summarized conceptually in Figure 1.
Figure 1. Metabolic reprogramming skews CD4 T-cell responses in TB-DM. High glucose and systemic inflammation in TB-DM patients reprogram CD4 T-cell metabolism, skewing the immune response from protective Th1 memory cells toward pathogenic Th17 cells. This shift contributes to impaired granuloma maintenance, tissue damage, and adverse clinical outcomes. Host-directed therapy strategies aim to restore Th1 function and reduce Th17-mediated pathology (15).
Translating cellular findings into host-directed therapy
These findings transition T2DM in the context of TB from a passive comorbidity to an active immune-metabolic disorder that detrimentally programs the host immune response (3, 7). This perspective demands a strategic pivot in therapeutic design (12):
1. Metabolic rescue of T-cells
If hyperglycaemia and associated metabolic stress are driving T-cell dysfunction, then intensive, individualized glycaemic control must be viewed as an indispensable form of HDT for TB-DM patients (12). We must move beyond simply monitoring HbA1c to ensuring that acute metabolic fluctuations are minimized, thereby reducing the environmental cues that favour Th17 differentiation and T-cell exhaustion.
2. Drug repurposing
The immunomodulatory effects of established DM medications must be systematically investigated. Drugs like Metformin have known pleiotropic effects on T-cell metabolism, potentially promoting Th1 responses or dampening Th17 differentiation through pathways like AMP-activated protein kinase (AMPK) (13). Exploring the impact of newer DM therapies, such as Sodium-Glucose Co-Transporter (SGLT) 2 inhibitors, on T-cell differentiation and cytokine profiles in TB-DM models is also crucial (14).
3. Phenotypic biomarkers
The goal is moving beyond broad DM screening to immunological risk stratification. We propose that developing simple, robust phenotypic markers, for instance specific cell surface markers associated with circulating Th1 exhaustion or Th17 fate, could identify DM patients with LTBI who are at the highest, most imminent risk of progression, allowing for targeted preventative therapy.
Conclusion
The pilot study on Th17 expansion and altered CD4 T cell differentiation provides important preliminary mechanistic insight, providing a much-needed molecular anchor for the devastating clinical reality of the TB-DM syndemic (4). T2DM does not merely coexist with TB; it reprograms the host adaptive immune system towards an ineffective total Th1 response and a destructive Th17-driven inflammatory state. Translational research must now urgently focus on metabolic and immunological rescue of the CD4 T cell population. By reversing these specific cellular defects, we can restore the immune system’s protective function, mitigate the risk of reactivation, and finally achieve durable cures in this challenging patient group. Ultimately, the pathways discussed herein represent theoretical targets that require rigorous validation in clinical settings to overcome the significant barriers of human patient variability and model fidelity.
Author contributions
HM: Conceptualization, Writing – original draft, Writing – review & editing. MS: Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. The authors would like to acknowledge the baseline funding from Biomedical Research and Innovation Platform of the South African Medical Research Council (SAMRC) (HM).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Author disclaimer
The content hereof is the sole responsibility of the authors and does represent the official views of the SAMRC.
References
1. Jeon CY and Murray MB. Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PloS Med. (2008) 5:e152. doi: 10.1371/journal.pmed.0050152
2. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med. (2011) 9:81. doi: 10.1186/1741-7015-9-81
3. Kumar Nathella P and Babu S. Influence of diabetes mellitus on immunity to human tuberculosis. Immunology. (2017) 152:13–24. doi: 10.1111/imm.12762
4. Ogongo P, Martinez-Lopez YE, Tran A, Lindestam Arlehamn CS, Sette A, Dominguez-Trejo IA, et al. Increased circulating Th17 cells and altered CD4 T cell maturation and differentiation in active tuberculosis with type 2 diabetes: a pilot study. Front Immunol. (2025) 16:1637868. doi: 10.3389/fimmu.2025.1637868
5. Guzzetta G and Kirschner D. The roles of immune memory and aging in protective immunity and endogenous reactivation of tuberculosis. PloS One. (2013) 8:e60425. doi: 10.1371/journal.pone.0060425
6. Arlehamn CSL, Gerasimova A, Mele F, Henderson R, Swann J, Greenbaum JA, et al. Memory T Cells in Latent Mycobacterium tuberculosis Infection Are Directed against Three Antigenic Islands and Largely Contained in a CXCR3+CCR6+ Th1 Subset. PloS Pathogens. (2013) 9:e1003130. doi: 10.1371/journal.ppat.1003130
7. Liang Y, Chen W, Gao Q, Tan KCB, Lee CH, and Ling GS. Metabolic hallmarks of type 2 diabetes compromise T cell function. Trends Endocrinol Metab. (2025). doi: 10.1016/j.tem.2025.08.005
8. Kumar NP, Moideen K, George PJ, Dolla C, Kumaran P, and Babu S. Coincident diabetes mellitus modulates Th1-, Th2-, and Th17-cell responses in latent tuberculosis in an IL-10- and TGF-β-dependent manner. Eur J Immunol. (2016) 46:390–9. doi: 10.1002/eji.201545973
9. Masood KI, Irfan M, Masood Q, Yameen M, Jamil B, Ram N, et al. Latent M. tuberculosis infection is associated with increased inflammatory cytokine and decreased suppressor of cytokine signalling (SOCS)-3 in the diabetic host. Scandinavian J Immunol. (2022) 95:e13134. doi: 10.1111/sji.13134
10. Ssekamatte P, Nabatanzi R, Sitenda D, Nakibuule M, Bagaya BS, Kibirige D, et al. Impaired Mycobacterium tuberculosis-specific T-cell memory phenotypes and functional profiles among adults with type 2 diabetes mellitus in Uganda. Front Immunol. (2024) 15:1480739. doi: 10.3389/fimmu.2024.1480739
11. Sun L, Wang L, Moore BB, Zhang S, Xiao P, Decker AM, et al. IL-17: balancing protective immunity and pathogenesis. J Immunol Res. (2023) 2023:3360310. doi: 10.1155/2023/3360310
12. Kim JS, Kim YR, and Yang CS. Host-directed therapy in tuberculosis: targeting host metabolism. Front Immunol. (2020) 11:1790. doi: 10.3389/fimmu.2020.01790
13. Duan W, Ding Y, Yu X, Ma D, Yang B, Li Y, et al. Metformin mitigates autoimmune insulitis by inhibiting Th1 and Th17 responses while promoting Treg production. Am J Trans Res. (2019) 11:2393–402.
14. Zhang R, Xie Q, Lu X, Fan R, and Tong N. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetol Metab Syndrome. (2024) 16:99. doi: 10.1186/s13098-024-01325-9
15. BioRender. Available online at: https://app.biorender.com/illustrations/canvas-beta/6916e5e5b2e34a7feb9e902d (Accessed November 14, 2025).
Keywords: CD4 T cell differentiation, immunometabolism, Th17 cells, tuberculosis, type 2 diabetes mellitus
Citation: Mutavhatsindi H and Shey M (2026) Commentary: Increased circulating Th17 cells and altered CD4 T cell maturation and differentiation in active tuberculosis with type 2 diabetes: a pilot study. Front. Immunol. 17:1750994. doi: 10.3389/fimmu.2026.1750994
Received: 04 December 2025; Accepted: 09 January 2026; Revised: 08 January 2026;
Published: 23 January 2026.
Edited by:
Esaki M. SHANKAR, Central University of Tamil Nadu, IndiaReviewed by:
Vinay Kumar Pathak, The Leprosy Mission Trust India, IndiaCopyright © 2026 Mutavhatsindi and Shey. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hygon Mutavhatsindi, SHlnb24ubXV0YXZoYXRzaW5kaUBtcmMuYWMuemE=